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Abstract 
Purpose: We report here the case of a patient with anterior segment migration of intravitreal 
dexamethasone implant as well as its management and outcome. Methods: The patient had 
the following sequence of events: complicated cataract surgery, iris-sutured intraocular lens 
implant, followed by cystoid macular edema treated with intravitreal Avastin, retinal vein 
occlusion treated with intravitreal dexamethasone implant, corneal decompensation treated 
with Descemet stripping automated endothelial keratoplasty (DSAEK), and finally recurrence 
of macular edema treated with repeated intravitreal dexamethasone implant. Results: Dexa-
methasone implant had completely dissolved from the eye 12 weeks after insertion without 
any complication. Conclusion: A conservative approach with regular monitoring in the situa-
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tion of a quiet anterior segment without any corneal decompensation can provide enough 
time for the implant to dissolve without causing any complication to the involved eye, avoid-
ing any additional surgical intervention, as presented in this case report. Despite the fact that 
the implant was left for natural dissolution, there were no adverse effects related to the graft 
or the eye. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Dexamethasone intravitreal implant (Ozurdex, Allergan Inc., Irvine, CA, USA) has been 
approved as a treatment option for macular edema secondary to retinal vein occlusion, non-
infectious uveitis affecting the posterior segment, and diabetic macular edema (DME) [1–3]. 
The Ozurdex implant is a biodegradable sustained-release device containing 0.7 mg dexame-
thasone in a solid polymer drug delivery system. In 2014, it was licensed for use in DME, and 
since then, retina specialists started to use it more frequently in DME cases not responding 
to anti-VEGF treatment and for DME cases with vitrectomized eyes [4]. These implants can 
sometimes migrate into the anterior chamber, causing vision-threatening complications that 
may involve permanent corneal decompensation [5–7]. This was initially reported in 
aphakic eyes where the authors speculated that aphakia was the main risk factor for anterior 
chamber migration [6]. 
Rarely, anterior chamber migration of the implant can also happen in vitrectomized 
eyes with compromised posterior capsule integrity [5]. It can potentially cause persistent 
corneal edema and ocular hypertension, therefore requiring intervention. The few cases 
already published have suggested first attempting positional maneuvers to reposition the 
implant, its surgical reinsertion or complete removal. 
Case Report 
A 74-year-old man, known for pseudoexfoliation, corneal guttata changes, and an epiret-
inal membrane, was treated with vitrectomy and membrane peel in August 2016. Later on, 
the patient underwent a complicated cataract surgery with an iris-sutured intraocular lens 
(IOL) in October 2016, followed by a first intravitreal injection of Avastin for cystoid macular 
edema in December 2016 and a second intravitreal injection of Avastin 4 weeks later. In 
February 2017, the patient was referred again with corneal edema and superior temporal 
branch retinal vein occlusion with macular edema. Visual acuity in the affected eye was rec-
orded as counting fingers, and the intraocular pressure was 20 mm Hg on Goldmann appla-
nation tonometry.  
The patient underwent a Descemet stripping automated endothelial keratoplasty 
(DSAEK), and 2 months later, corneal transparency was achieved. Due to persistent macular 
edema, an additional intravitreal Ozurdex implant was administered 3 months after DSAEK 
in the same eye. Two weeks after insertion, the intravitreal Ozurdex implant became visible 
in the pupillary area, positioning itself between the iris and the IOL’s optic and protruding in 
the anterior chamber without any corneal touch. The visual acuity was recorded as 3/10, the 
corneal graft was clear without any corneal edema. The intraocular pressure was recorded 
as 18 mm Hg on Goldmann applanation tonometry. A decision was made to keep the patient 
under close observation as there was no corneal touch and no clinically significant corneal 
edema as seen in Figure 1. 
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Four weeks later, signs of implant dissolution were seen (Fig. 2). Eight weeks later, the 
implant had completely dissolved (Fig. 3), the corneal graft remained clear, and there was no 
abnormal increase in intraocular pressure. At the last clinical visit, visual acuity improved to 
5/10 (best corrected distance visual acuity). Recurrence of macular edema was noticed 
again, and a course of intravitreal Eylea treatment was planned. 
Discussion 
Khurana et al. [7] reported the largest series of patients with Ozurdex implant with an-
terior chamber migration and reviewed the risk factors, clinical complications, and man-
agement options. The authors described 15 patients with 18 episodes of anterior chamber 
migration of the Ozurdex implant. History of vitrectomy and either an absent or defective 
lens capsule were the commonest risk factors. 
Patients with previous vitrectomy, aphakia, zonular dehiscence, and large peripheral ir-
idotomy may have an increased risk of implant migration into the anterior chamber and 
should be closely monitored for possibility of implant migration [8]. Similarly to our case, 
there have been case reports with prior uncomplicated dexamethasone implant injections 
with the same lens and capsule status [7]. 
Corneal edema is the most serious complication of Ozurdex implant migration in the an-
terior chamber, and it has been reported in 89% of patients at presentation [7]. Further-
more, the corneal edema may not resolve spontaneously despite implant removal in 71% of 
cases, and 43% may need corneal graft [7]. 
Endothelial decompensation is either due to chemical toxicity from any component of 
the Ozurdex implant (dexamethasone, lactic acid, or glycolic acid) or to endothelial touch, 
where the direct mechanical trauma from a rigid object is responsible for corneal edema. 
Specular microscopy has demonstrated loss of corneal endothelial cells with the anterior 
chamber implant migration [9]. High doses of dexamethasone can be cytotoxic and can in-
duce apoptosis and necrosis of corneal endothelial cells [10]. 
Corneal edema occurs in cases with early migration (within less than 3 weeks) and re-
quires urgent intervention [7]. With late migration (occurring after 3 weeks), the implant 
may have already degraded enough to cause minimal corneal toxicity (hence there are less 
chances of corneal edema) and can be observed closely [6, 7, 9, 11]. 
Management options include observation, supine positioning, YAG fragmentation and 
surgical removal involving either forceps, aspiration of implant’s fragments, or repositioning 
into the posterior chamber. Pupil constriction with pilocarpine is indicated primarily in 
high-risk patients or following repositioning in order to minimize the risk of repeat anterior 
chamber implant migration, but recurrence of anterior migration can still happen [6]. 
A slit-lamp procedure where the implant is repositioned posteriorly using a needle is an 
option as well, but the implant may come back into the anterior chamber [12]. The implant 
can be friable and so can be a challenge to remove in one piece, thus it can be aspirated with 
a vitrectomy cutter [7]. Investigators have proposed a technique of scleral fixation of the 
Ozurdex implant in the vitreous cavity with a 10-0 polypropylene suture in high-risk pa-
tients [13]. 
In our case, there was no corneal edema at presentation or subsequently, and the 
DSAEK graft remained clear. Intraocular pressure remained within normal limits. Consider-
ing the risks of surgical intervention, including endophthalmitis, damage to the IOL, or fail-
ure of the corneal graft, we decided that close observation was the best management option.  
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Anterior migration of Ozurdex implant can happen in vitrectomized eyes and in eyes 
with zonular dehiscence or compromised posterior capsule. Management of this situation is 
crucial, and the diagnosis may be delayed due to the increased follow-up intervals allowed 
by these injections. Additionally, the frailty of the implant itself makes surgical treatment 
difficult. Eyes with anterior segment surgery, such as corneal grafting, are at higher risk of 
graft rejection or corneal decompensation. However, a conservative approach with regular 
monitoring in the situation of a quiet anterior segment without any corneal decompensation 
can provide enough time for the implant to dissolve without causing any complication to the 
involved eye, avoiding any additional surgical intervention, as presented in this case report.  
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Fig. 1. Photo of the anterior segment showing the dislocated Ozurdex implant in the pupil at week 4. 
 
 
 
Fig. 2. Photo of the anterior segment showing the dissolving Ozurdex implant in the pupil at week 8. 
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Fig. 3. Photo of the anterior segment showing that the Ozurdex implant was dissolved at week 12. 
 
